Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Bailong Chuangyuan Bio-Tech is a leading Chinese manufacturer specializing in the research, production, and sales of prebiotics, dietary fibers, healthy sweeteners, and other starch-based sugar products. Its core products include resistant dextrin, oligofructose, isomalt-oligosaccharide, polydextrose, galacto-oligosaccharide, xylo-oligosaccharide, allulose (a rare sugar), maltitol among others. The company positions its products at the mid-to-high end of the market and has received numerous national awards for innovation and intellectual property. It is recognized as a flagship enterprise in China’s “Functional Sugar City” cluster. The company went public on the Shanghai Stock Exchange main board in April 2021.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Bailong Chuangyuan Bio-Tech.